Table 4. Comparative treatment outcomes of 106Ru plaque therapy for CCH.
| Parameters | Present study | Medraperla et al[5] | Naseripour et al[9] | Joshi et al[21] |
| No. of patients | 25 | 8 | 21 | 8 |
| Radioactive isotope | 106Ru | 106Ru and iodine-125 | 106Ru | 106Ru |
| Dose, Gy, mean | 84.4 | 50 | 38.5 | 32.5 |
| Radiation-related complication, n (%) | ||||
| Retinopathy | 2 (8) | 0 | 5 (23.8) | 0 |
| Papillopathy | 0 | 0 | 1 (4.8) | 0 |
| Mean tumor height, mm | ||||
| Baseline | 3.99 | 4.8 | 3.87 | 5.0 |
| Last visit | 0.84 | 2.1 | 0.7 | Not reported |
| GLD, mm, mean | ||||
| Baseline | 9.36 | 10.6 | 10.0 | 12.7 |
| Last visit | 7.40 | Not reported | 8.33 | Not reported |
| BCVA, mean | ||||
| Baseline | ≈20/200 | 20/80 | 20/80 | Not reported |
| Last visit | ≈20/160 | 20/30 | 20/50 | Not reported |
| Visual acuity improvement, % | Two or more lines, 52 | Three or more lines, 63 | Two or more lines, 57 | Not reported |
| Follow-up period, mo, mean | 28.0 | 25.0 | 38.6 | Not reported |
CCH: Circumscribed choroidal hemangioma; BCVA: Best-corrected visual acuity; GLD: The greatest linear diameter.